Taiwan
· Delayed Price · Currency is TWD TaiMed Biologics Company Description
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases.
It develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment.
The company is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates, for cancer treatment.
In addition, it offers contract development and manufacturing services. The company has a research and development agreement for Trogarzo TMB-355 with Genentech and Biogen Inc., and authorizes Samsung Biologics to produce TMB-355.
TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei City, Taiwan.
| Country | Taiwan |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Chin-Ming Chang |
Contact Details
Address: NO. 607, Ruiguang Rd. Taipei City, 11492 Taiwan | |
| Phone | 886 2 2658 0058 |
| Website | taimedbiologics.com |
Stock Details
| Ticker Symbol | 4147 |
| Exchange | Taipei Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0004147004 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Chin-Ming Chang Ph.D. | President and Chief Executive Officer |
| Dr. David D. Ho M.D. | Scientific Co-Founder, Chief Scientific Advisor and Board Director |
| Dr. Ing-Wen Tsai Ph.D. | Co-Founder |
| Dr. Lan-Bo Chen Ph.D. | Co-Founder |
| Jack Chen CPA | Chief Financial Officer and Chief of Corporate Governance |